Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.53% | 4.72% | 4.00% | 9.80% | 9.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.74% | 8.19% | 6.06% | 9.75% | 12.07% |
| Operating Income | -5.74% | -8.19% | -6.06% | -9.75% | -12.07% |
| Income Before Tax | 54.48% | -72.86% | -128.92% | -198.13% | -147.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.48% | -72.86% | -128.92% | -198.13% | -147.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.48% | -72.86% | -128.92% | -198.13% | -147.31% |
| EBIT | -5.74% | -8.19% | -6.06% | -9.75% | -12.07% |
| EBITDA | -5.66% | -8.13% | -6.01% | -9.73% | -12.14% |
| EPS Basic | 58.43% | -65.49% | -123.62% | -192.70% | -122.40% |
| Normalized Basic EPS | 58.38% | -65.72% | -124.12% | -193.05% | -122.60% |
| EPS Diluted | 58.43% | -65.49% | -123.62% | -192.70% | -122.40% |
| Normalized Diluted EPS | 58.38% | -65.72% | -124.12% | -193.05% | -122.60% |
| Average Basic Shares Outstanding | 10.09% | 7.06% | 4.05% | 3.73% | 7.60% |
| Average Diluted Shares Outstanding | 10.09% | 7.06% | 4.05% | 3.73% | 7.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |